San Francisco, CA, United States of America

Pierre-Jean Colson

This inventor holds 31 USPTO granted patents and 2 published patent applications, plus 7 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Theravance, Inc., Theravance Biopharma R&d IP, LLC. Active years: 2008-2023.

USPTO Granted Patents = 31 

% Patents Active = 61.3

 

 

Average Co-Inventor Count = 2.9

ph-index = 10

Forward Citations = 246(Granted Patents)


Location History:

  • South San Francisco, CA (US) (2020)
  • San Francisco, CA (US) (2008 - 2023)

Company Filing History:


Years Active: 2008-2023

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
JAK Inhibitors
Opioid Receptor Antagonists
Biphenyl Compounds
Crystalline Forms
Aminotetralin Derivatives
Beta2 Adrenergic Agonists
Muscarinic Receptor Antagonists
Intermediates Preparation
31 patents (USPTO):Explore Patents

Title: Inventor Pierre-Jean Colson: Revolutionizing Technology in San Francisco

Introduction: Pierre-Jean Colson is a visionary inventor based in San Francisco, CA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Pierre-Jean Colson holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and creativity.

Career Highlights: With a career spanning over two decades, Pierre-Jean Colson has worked with leading tech companies in Silicon Valley, spearheading projects that have pushed the boundaries of what is possible in the tech industry.

Collaborations: Throughout his career, Pierre-Jean Colson has collaborated with top researchers, engineers, and scientists from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion: Pierre-Jean Colson continues to be a driving force in the world of technology, with his innovative spirit and passion for creating a better future through his inventions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…